Happy to share my first publication as a corresponding author!
My sincere thanks to my mentor, @Ramande39667129, for his continued support and guidance and @DBTIndia for the funding.
#ScientificResearch #ResearchJourney #Publication #DrugDiscovery
New research highlights a promising drug-repurposing strategy for #Tuberculosis!
FDA-approved benzatropine inhibits intracellular growth of both drug-sensitive & drug-resistant M. tuberculosis in vitro and in vivo, boosts rifampicin & pretomanid activity, and works by inducing host macrophage autophagy via the JAK2/STAT3 & AMPK pathways.
🔗 tinyurl.com/4zajjfes
@DBTIndia @BricDbt @rajesh_gokhale @drkarthik2010 @Ramande39667129
7
Niranjana Sri S, Ph.D. retweeted
New research highlights a promising drug-repurposing strategy for #Tuberculosis!
FDA-approved benzatropine inhibits intracellular growth of both drug-sensitive & drug-resistant M. tuberculosis in vitro and in vivo, boosts rifampicin & pretomanid activity, and works by inducing host macrophage autophagy via the JAK2/STAT3 & AMPK pathways.
🔗 tinyurl.com/4zajjfes
@DBTIndia @BricDbt @rajesh_gokhale @drkarthik2010 @Ramande39667129
Niranjana Sri S, Ph.D. retweeted
Congratulations to the team and happy to contribute: Delineating the Mechanism of Action of the Repurposed Drug Benzatropine against Mycobacterium tuberculosis @Ramande39667129 pubs.acs.org/aidcbc/article-…
Niranjana Sri S, Ph.D. retweeted
Happy to share this work from the lab @THSTIFaridabad. Led by Neelam, @gopinathchatt, @niranjanasris. Here, we have studied the physiological roles and cross talk of VapBC35 TA systems from M. tuberculosis. Thanks to @India_Alliance for their funding
rdcu.be/ebzZO





